People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vanqua Bio, Inc. | — | Biotechnology | Series C | $136.0M | $462.9M | 2019 |
| Prevail Therapeutics Inc. | — | Pharma | Series C | $57.0M | $2.0B | 2018 |
Mona Ashiya at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mona Ashiya on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Peter Thompson | 1 | 16 |
| Jonathan Silverstein | 1 | 10 |
| Stephen Squinto | 1 | 8 |
| James Sullivan | 1 | 7 |
| Sara Nayeem | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
| Rand Sutherland | 1 | 1 |
| Uya Chuluunbaatar | 1 | 1 |
| Viola Meehan | 1 | 1 |
| ASA ABELIOVICH | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.